BPC-157 - Hemi Pharma

BPC-157, short for Body Protection Compound 157, was first studied in 1992 under the direction of Croatian researcher Predrag Sikiric. The peptide was derived from a natural protein found in human gastric juice and showed promise in early laboratory trials for tissue repair and regenerative uses. Most of the pioneering work took place in Croatia and was funded by Pliva, a local pharmaceutical firm, though support ended in 2005. Afterward, Merck attempted to acquire rights but did not succeed. Today, BPC-157 is sold as a research chemical, with Diagen of Slovenia as its top producer.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about BPC-157 by Hemi Pharma, consult with your doctor or healthcare professional.